JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C100699200 on December 27, 2001

J. Biol. Chem., Vol. 277, Issue 9, 6767-6770, March 1, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/9/6767    most recent
C100699200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, Y. K.
Right arrow Articles by Lanier, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, Y. K.
Right arrow Articles by Lanier, S. M.

ACCELERATED PUBLICATION
Identification of Structural Features in the G-protein Regulatory Motif Required for Regulation of Heterotrimeric G-proteins*

Yuri K. Peterson, Starr Hazard IIIDagger , Stephen G. Graber§, and Stephen M. Lanier

From the Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Science Center, New Orleans, Louisiana 70118, the Dagger  Department of Library and Informatics, Medical University of South Carolina, Charleston, South Carolina 29425, and the § Department of Biochemistry and Molecular Pharmacology, West Virginia University School of Medicine, Morgantown, West Virginia 26506

Received for publication, December 3, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The G-protein regulatory (GPR) motif, a conserved 25-30 amino acid domain found in multiple mammalian proteins, stabilizes the GDP-bound conformation of Galpha i, inhibits guanosine 5'-O-(3-thiotriphosphate) (GTPgamma S) binding to Galpha i and competes for Gbeta gamma binding to Galpha . To define the core GPR motif and key amino acid residues within a GPR peptide (TMGEEDFFDLLAKSQSKRMDDQRVDLAG), we determined the effect of truncation, insertion, and alanine substitutions on peptide-mediated inhibition of GTPgamma S binding to purified Galpha i1. The bioactive core GPR peptide consists of 17 amino acids (7F-R23). Within this core motif, two hydrophobic sectors (7FF8 and 10LL11) and Q22 are required for bioactivity, whereas M19A and R23A increased IC50 values by 70-fold. Disruption of spatial relationships between the required sectors in the amino and carboxyl regions of the peptide also resulted in a loss of biological activity. Mutation of three charged sectors (4EED6, R18, 20DD21) within the 28-amino acid GPR decreased peptide affinity by ~10-fold. Alanine substitutions of selected residues within the core GPR peptide differently influenced peptide inhibition of GTPgamma S binding to Galpha i versus Galpha o. These data provide a platform for the development of novel, G-protein-selective therapeutics that inhibit Galpha i-mediated signaling, selectively activate Gbeta gamma -sensitive effectors, and/or disrupt specific regulatory input to G-proteins mediated by GPR-containing proteins.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The activation/deactivation cycle of heterotrimeric G-proteins, key players in cell signaling events, involves guanine nucleotide exchange, GTP hydrolysis, and a number of dynamic, conformationally sensitive protein interactions. In addition to the extensively studied activation of G-proteins by the superfamily of G-protein-coupled receptors, the G-protein activation/deactivation cycle is regulated by nonreceptor proteins that influence subunit interactions, GTPase activity, and guanine nucleotide binding properties of Galpha . One signature motif for such regulatory proteins is the regulator of G-protein signaling (RGS)1 domain, a ~120-amino acid motif found in all members of the RGS family (1). Another signature motif (~25-30 amino acids) is defined by the G-protein regulatory (GPR) domain in activator of G-protein signaling (AGS) 3 (2-6), which was discovered in a functional screen for receptor-independent activators of G-protein signaling. The GPR motif was also recognized in RGS12 and RGS14 by general sequence analysis/alignment and termed the GoLOCO motif (7, 8).

Surprisingly, interaction of the GPR motif with Galpha i stabilizes the GDP bound conformation of Galpha i, competes with Gbeta gamma for Galpha binding, and inhibits guanine nucleotide exchange (3-6, 9-12). Thus, the GPR motif acts as a guanine nucleotide dissociation inhibitor of Galpha i. The GPR motif is evolutionarily conserved within individual orthologs and among proteins with apparently diverse functions (see S.M.A.R.T. data base at dylan.embl-heidelberg.de/). Four spatially conserved GPR motifs are found in AGS3 (3) and LGN (13), which were isolated as Galpha i-regulatory/binding proteins. Recombinant AGS3 constructs with more than one GPR motif actually bind more than one Galpha i at the same time (5), suggesting a scaffolding role for such proteins. The AGS3/LGN-related protein PINS, which plays key roles in cell polarity (14-17), possesses a similar domain structure. The interaction of the PINS protein GPR domains with Galpha is involved in the function of PINS in cell polarity and asymmetric cell division (17). AGS3 is also involved in synaptic adaptation in rat models of addiction (22). Single GPR motifs are found in Rap1GAP, Pcp2, RGS12, and RGS14, which are all implicated as G-protein regulators. Protein interaction studies and/or functional screens in yeast indicate that the AGS3 GPR motif interacts with Galpha i1-3, but not Galpha s, Galpha q, Galpha z, Galpha 12, or Galpha 16 (3, 5, 11). Specific GPR motifs are capable of interacting with Galpha o, albeit with apparently lower affinity than observed for Galpha i (10). Rap1GAP was actually isolated in yeast two-hybrid screens using Galpha o (18) and Galpha z (19), whereas Pcp2 was isolated in similar screens using Galpha o (20). Thus the GPR motif appears to serve as a discrete motif to anchor a variety of proteins that influence the guanine nucleotide binding/hydrolysis properties of G-proteins.

The existence of such a fairly discrete and highly conserved binding motif that inhibits GDP dissociation is of particular interest. As a first step toward developing a small organic molecule that would mimic the action of a GPR peptide, we defined the key structural features of the GPR motif required for biological activity. These data provide a platform for the development of novel, G-protein-selective therapeutics that target this critically important signaling protein within the cell. Such agents might inhibit Galpha -mediated signaling by G-protein-coupled receptors, selectively activate Gbeta gamma -sensitive effectors, and/or disrupt specific regulatory input to G-proteins mediated by GPR-containing proteins.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- Peptides were synthesized and purified by Bio-Synthesis, Inc. (Lewisville, TX) and peptide identity verified by matrix-assisted laser desorption ionization mass spectrometry. Peptides were synthesized with an acetylated amino terminus and an amidated carboxyl terminus. All other materials were obtained as described elsewhere (3-5).

GTPgamma S Binding and Protein Interaction Assays-- GTPgamma S binding assays and protein interaction assays were conducted as described previously (4, 5). The GPR domain of AGS3 (463P-S650) was generated as a gutathione S-transferase fusion protein in pGEX4T1. GST-AGS3 was expressed in and purified from BL21 bacteria using glutathione-Sepharose 4B. Galpha i1 and Galpha o were purified in the GDP bound state from Sf9 insect cells infected with recombinant virus as described previously (21). Concentration response curves with GPR peptides were analyzed by PRISM (Graphpad Software, Inc, San Diego, CA) to calculate IC50 values.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Stabilization of the GDP-bound conformation of Galpha i by a 28-amino acid peptide encompassing the GPR motif presents an unexpected aspect of regulation within the G-protein activation/deactivation cycle. This activity of the peptide essentially prevents nucleotide exchange on Galpha and binding of GTP to G-protein. The GPR-Galpha iGDP complex is quite stable and is observed in the absence and presence of added magnesium, which is generally required for high affinity binding of GTPgamma S (Fig. 1). As part of a broad approach to define the structural properties of this regulation and develop a small molecule ligand that would target this novel regulatory site on Galpha subunits, we defined the core GPR motif and the key amino acid residues within this core motif. A panel of peptides derived from the GPR motif were characterized in GTPgamma S binding assays and protein interaction assays using purified mammalian G-protein alpha  subunits.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of magnesium on inhibition of GTPgamma S binding to Galpha i. GTPgamma 35S (500 nM) binding (using 0 and 25 mM MgCl2) to Galpha i (100 nM) was measured in absence and presence of increasing amounts of GPR peptide as described under "Experimental Procedures." Data are expressed as the percent of specific binding (~2 pmol) observed in the absence of added peptide and are expressed as the mean ± S.E. of two experiments with duplicate determinations.

Several conserved features constitute the GPR motif. The invariant Q15 essentially divides the peptide into two general regions of conserved residues (Fig. 2A). Both helical wheel and hydrophobic moment analysis indicate that the area upstream of Q15 likely exists as an alpha helix. We first asked if either of the two general regions of conserved residues (i.e. upstream and downstream of Q15) were active by themselves. Neither GPR1-15 nor GPR15-28 inhibited GTPgamma S binding to Galpha i. The region upstream of Q15 is distinguished by the negatively charged 4EED6 followed by two hydrophobic sectors (7FF8, 10LL11) (Fig. 2). The region downstream of the Q15 peptide is characterized by the conserved sequence 18RMDDQR23. Deletion of the first eight residues at the amino terminus, which removed 7FF8 or mutation of R23 to phenylalanine (3-5), resulted in an inactive peptide indicating that the minimal sequence for bioactivity is 7F-R23 (Fig. 2A). The 20DDQR23 sequence is one of the most highly conserved regions of the peptide among different species and proteins. To test the importance of the spatial relationship between this region and the remainder of the conserved residues found elsewhere in the peptide, we inserted two and four alanines just upstream of the 20DDQR23 region. Insertion of the alanines completely abolished bioactivity in GTPgamma S binding assays (Fig. 2A). Thus, these data indicated that there is a core GPR motif (residues 7-23) in which a defined spatial relationship among the conserved residues is required for bioactivity.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Identification of the core GPR motif. A: left panel, amino acid sequence of GPR peptide and truncated GPR peptides. Consensus amino acids are depicted in red. The right panel portrays GTPgamma S binding (500 nM with 2 mM MgCl2) to Galpha i (100 nM) measured in the absence and presence of GPR peptides (100 µM) as described under "Experimental Procedures." Data are expressed as the percent of specific binding (~1 pmol) observed in the absence of added peptide and are expressed as the mean ± S.E. of two experiments with duplicate determinations. Similar results were obtained in two to five separate experiments. B: left panel, sequence alignment and IC50 values of mutated GPR peptides. Conserved amino acids are depicted in red, and mutated amino acids are colored green. Right panel, effect of increasing concentrations of competing peptides on GTPgamma S (500 nM with 2 mM MgCl2) binding to Galpha i (100 nM). Data are expressed as the percent of specific binding (~1 pmol) observed in the absence of added peptide and are expressed as the mean ± S.E. of two experiments with duplicate determinations. Similar results were obtained in two to five separate experiments. Inactive, inhibition of GTPgamma S binding was less than 30% at peptide concentrations of 100 µM.

We then addressed the relative importance of conserved amino acids within the core GPR motif by alanine substitutions and subsequent peptide evaluation in GTPgamma S binding assays (Fig. 2B). Peptides with alanine substitutions at 7FF8, 10LL11, and Q22 were inactive and thus identify the key residues of the peptide. Both 7FF8 and 10LL11 likely constitute the core of the predicted alpha helix in this region, indicating the importance of this structural feature for bioactivity (Fig. 1). The importance of this region is further emphasized by loss of biological activity observed with an F8R mutation in the context of a GST-AGS3 fusion protein (3, 5, 17). The IC50 values for D9A, K13A, Q15A, and S16A peptides were similar to the consensus GPR peptide (Fig. 2B). Alanine substitutions at the other key residues within the GPR motif indicated that the residues could be grouped as those causing 7-10-fold (4EED6, R18, and 20DD21) or 50-70-fold (M19 and R23) shifts in IC50 values (Fig. 2B). The loss of affinity observed with the alanine substitutions at 4EED6 are consistent with the retention of bioactivity by the truncation mutant GPR3-24, whereas the loss of activity with the 7FF8 alanine substitutions was also observed by elimination of these residues in the GPR10-24 truncated peptide. The larger reduction in affinity observed with the M19 and R23 alanine substitutions indicate the importance of these residues within the core GPR peptide. Indeed, reversal of charge or hydrophobicity at these residues (M19D and R23F) essentially rendered these peptides inactive (3-5).2

The inhibition of GTPgamma S binding and apparent stabilization of the GDP-bound conformation of Galpha i by the GPR peptide likely involves two events, the initial binding of the peptide to G-protein, followed by a conformational change in Galpha i itself. To determine whether the two events can be functionally dissociated, we performed two series of experiments. We first asked if mutant peptides that exhibited lower affinity in GTPgamma S binding assays were also deficient in inhibiting binding of a GPR-containing GST-AGS3 fusion protein to Galpha i. In the second series of experiments, we determined whether truncated GPR peptides could act in a complementary fashion and whether they could antagonize the action of the GPR consensus peptide. Data generated from this series of experiments indicated that the loss of function in binding studies was also reflected in the protein interaction assays (Fig. 3, A and B). The partial inhibition of GST-AGS3 binding to G-protein in the presence of GPR6-24 indicates that this peptide is not as potent as GPR3-24 or wild type peptide, likely due to the loss of the 4EED6 acidic cluster (Fig. 2, A and B, and Fig. 3B). These data indicated that G-protein interaction and inhibition of GTPgamma S binding could not be dissociated from each other. This point is further emphasized by data generated in another series of experiments (Fig. 3C). A combination of the inactive GPR truncation peptides (GPR 1-15 and GPR 15-28) did not inhibit binding of GST-AGS3 to Galpha i. Neither of the peptides antagonized the action of the consensus GPR peptide nor were they able to rescue the activity of nonfunctional, alanine-substituted GPR peptides (Fig. 3). These data confirm the importance of the spatial relationship within the core GPR motif. These data also indicate that the GPR domain must function as an intact unit and that there are multiple points of contact between the GPR domain and Galpha .


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of GPR peptides on binding of Galpha i to AGS3. Protein interaction assays were performed as described under "Experimental Procedures" using 75 nM Galpha i1 and 300 nM GST-AGS3 in the presence of 10 µM GDP. Peptide concentration is 100 µM in A and B. The peptide concentration was 10 µM in C except for the four lanes at the right of the panel where the truncated GPR peptides were present at 100 µM. Similar results were obtained in two to three separate experiments.

Although the GPR peptide clearly prefers Galpha i over Galpha o, subtle mutations within the core motif differentially effect peptide interaction with the two G-proteins (Fig. 4A). A screen of the mutant GPR peptides for selectivity indicated that inhibition of GTPgamma S binding to Galpha o is completely eliminated by alanine substitutions within the core GPR motif that only minimally altered GTPgamma S binding to Galpha i (Fig. 4A). The difference in the interaction of the GPR peptide with Galpha i versus Galpha o is also observed by comparing the relative inhibition of GTPgamma S binding in the presence and absence of magnesium. The inhibition of GTPgamma S binding to Galpha o is much more sensitive to magnesium as compared with the effects of the peptide on Galpha i (Fig. 4B). These data indicate that the GPR peptides can differentially target G-protein alpha  subunits. Amino acids outside the GPR motif may also influence G-protein selectivity or bioactivity (see Discussion in Ref. 4).3


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of GPR peptides on GTPgamma S binding to Galpha i versus Galpha o. A, GTPgamma 35S binding (500 nM) to purified G-protein (100 nM) was determined as described under "Experimental Procedures" as detailed in the legend to Fig. 1 in the absence and presence of 10 µM peptide. Assays were conducted in parallel using the same stocks of GTPgamma S and peptides. Data are expressed as the percent of specific binding (Galpha i ~ 2 pmol, Galpha o ~ 1 pmol). B, GTPgamma 35S (500 nM) binding (using 0 and 25 mM MgCl2) to Galpha i or Galpha o (100 nM) was measured in absence and presence of 100 µM GPR peptide as described under "Experimental Procedures." The increased GTPgamma S binding to Galpha o in the presence of selected peptides was also observed with similar amounts of bovine serum albumin, suggesting that it does not likely represent an actual increase in nucleotide exchange, per se, but rather enhanced protein recovery. Data are expressed as the percent of specific binding (~1 pmol for Gi and Go) observed in the absence of added peptide and are expressed as the mean ± S.E. of two experiments with duplicate determinations.

The core GPR motif identified in the present study is indicated in Sequence 1. 
<UP>FF-LL-------M--QR</UP>

<UP><SC>Sequence</SC> 1</UP>
Within this core, 7FF8, 10LL11, and Q22 are absolutely required for bioactivity. The carboxyl terminus R23 and the M19 residue also play key roles in bioactivity as their mutation results in large shifts in affinity. Within the larger GPR peptide (Sequence 2),
<UP>EE-FF-LL------RMDDQR</UP>

<UP><SC>Sequence</SC> 2</UP>
4EE5, 20DD21, and the internal R18 all exert effects on affinity (~7-10-fold). Minimizing the core GPR motif to its essential pharmacophores identified the chemical moieties within the GPR motif that regulate Gi/Go nucleotide exchange. By virtue of its novel mode of regulation of G-proteins, the core GPR motif provides an unexpected platform for the development of G-protein selective therapeutics.

    ACKNOWLEDGEMENTS

We thank Joe Blumer (Louisiana State University Health Sciences Center) for suggestions and review of this work. We also appreciate discussions with Michael Bernard (Medical University of South Carolina) and Stephen Sprang (University of Texas Southwestern); the footnoted communication from Randall Kimple, David Siderovski, and John Sondek (University of North Carolina School of Medicine); and the technical assistance of Jane Jourdan and Maureen Fallon.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants NS24821 and MH5993 (to S. M. L.) and National Science Foundation Grant MCB9870839 (to S. G. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Pharmacology, MEB Suite 7103, LSUHSC, 1901 Perdido St., New Orleans, LA 70112. Tel.: 504-568-4744; Fax: 504-568-2361; E-mail: slanie@lsuhsc.edu.

Published, JBC Papers in Press, December 27, 2001, DOI 10.1074/jbc.C100699200

2 Y. K. Peterson and S. M. Lanier, unpublished observations.

3 R. Kimple, J. Sondek, and D. P. Siderovski, personal communication.

    ABBREVIATIONS

The abbreviations used are: RGS, regulator of G-protein signaling; GPR, G-protein regulatory; AGS, activator of G-protein signaling; GTPgamma S, guanosine 5'-O-(3-thiotriphosphate); GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Ross, E. M., and Wilkie, T. M. (2000) Annu. Rev. Biochem. 69, 795-827[CrossRef][Medline] [Order article via Infotrieve]
2. Cismowski, M., Takesono, A., Ma, C., Lizano, J. S., Xie, S., Fuernkranz, H., Lanier, S. M., and Duzic, E. (1999) Nat. Biotechnol. 17, 878-883[CrossRef][Medline] [Order article via Infotrieve]
3. Takesono, A., Cismowski, M. J., Ribas, C., Bernard, M., Chung, P., Hazard, S., III, Duzic, E., and Lanier, S. M. (1999) J. Biol. Chem. 274, 33202-33205[Abstract/Free Full Text]
4. Peterson, Y. K., Bernard, M. L., Ma, H., Hazard, S., III, Graber, S. G., and Lanier, S. M. (2000) J. Biol. Chem. 275, 33193-33196[Abstract/Free Full Text]
5. Bernard, M. L., Peterson, Y. K., Chung, P., Jordan, J., and Lanier, S. M. (2001) J. Biol. Chem. 276, 1585-1593[Abstract/Free Full Text]
6. Natochin, M., Lester, B., Peterson, Y. K., Bernard, M. L., Lanier, S. M., and Artemyev, N. O. (2000) J. Biol. Chem. 275, 40981-40985[Abstract/Free Full Text]
7. Ponting, C. P. (1999) J. Mol. Med. 77, 695-698[CrossRef][Medline] [Order article via Infotrieve]
8. Siderovski, D. P., Diverse-Pierlussi, M. A., and De Vries, L. (1999) Trends Biochem. Sci. 24, 340-341[CrossRef][Medline] [Order article via Infotrieve]
9. Pizzinat, N., Takesono, A., and Lanier, S. M. (2001) J. Biol. Chem. 276, 16601-16610[Abstract/Free Full Text]
10. Natochin, M., Gasimov, K. G., and Artemyev, N. O. (2001) Biochemistry 40, 5322-5328[Medline] [Order article via Infotrieve]
11. De Vries, L., Fischer, T., Tronchere, H., Brothers, G. M., Strockbine, B., Siderovski, D. P., and Farquhar, M. G. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 14364-14369[Abstract/Free Full Text]
12. Kimple, R. J., De, Vries, L., Tronche`re, H., Behe, C. I., Morris, R. A., Farquhar, M. G., and Siderovski, D. P. (2001) J. Biol. Chem. 276, 29275-29281[Abstract/Free Full Text]
13. Mochizuki, N., Cho, G., Wen, B., and Insel, P. A. (1996) Gene (Amst.) 181, 39-43[CrossRef][Medline] [Order article via Infotrieve]
14. Yu, F. W., Morin, X., Cai, Y., Yang, X. H., and Chia, W. (2000) Cell 100, 399-409[CrossRef][Medline] [Order article via Infotrieve]
15. Schaefer, M., Schevchenko, A., Schevchenko, A., and Knoblich, J. A. (2000) Curr. Biol. 10, 353-362[CrossRef][Medline] [Order article via Infotrieve]
16. Bellaïche, Y., Radovic, A., Woods, D. F., Hough, C. D., Parmentier, M.-L., O'Kane, C. J., Bryant, P. J., and Schweisguth, F. (2001) Cell 106, 355-366[CrossRef][Medline] [Order article via Infotrieve]
17. Schaefer, M., Petronczki, M., Dorner, D., Forte, M., and Knoblich, J. A. (2001) Cell 107, 183-194[CrossRef][Medline] [Order article via Infotrieve]
18. Jordan, J. D., Carey, K. D., Stork, P. J. S., and Iyengar, R. (1999) J. Biol. Chem. 274, 21507-21510[Abstract/Free Full Text]
19. Meng, J., Glick, J. L., Polakis, P., and Casey, P. J. (1999) J. Biol. Chem. 274, 36663-36669[Abstract/Free Full Text]
20. Luo, Y., and Denker, B. M. (1999) J. Biol. Chem. 274, 10685-10688[Abstract/Free Full Text]
21. Clawges, H. M., Depree, K. M., Parker, E. M., and Graber, S. G. (1997) Biochemistry 36, 12930-12938[CrossRef][Medline] [Order article via Infotrieve]
22. Bowers, S., Lanier, S. M., and Kalivas, P. (2001) Annual Meeting of the Society of Neuroscience, November 11-15, San Diego, CA, Abstract Program 977.6


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Sato, M. J. Cismowski, E. Toyota, A. V. Smrcka, P. A. Lucchesi, W. M. Chilian, and S. M. Lanier
Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gbeta{gamma}
PNAS, January 17, 2006; 103(3): 797 - 802.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. W. Ja, A. Adhikari, R. J. Austin, S. R. Sprang, and R. W. Roberts
A Peptide Core Motif for Binding to Heterotrimeric G Protein {alpha} Subunits
J. Biol. Chem., September 16, 2005; 280(37): 32057 - 32060.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Cho, D.-U. Kim, and J. H. Kehrl
RGS14 Is a Centrosomal and Nuclear Cytoplasmic Shuttling Protein That Traffics to Promyelocytic Leukemia Nuclear Bodies Following Heat Shock
J. Biol. Chem., January 7, 2005; 280(1): 805 - 814.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Cao, M. J. Cismowski, M. Sato, J. B. Blumer, and S. M. Lanier
Identification and Characterization of AGS4: A PROTEIN CONTAINING THREE G-PROTEIN REGULATORY MOTIFS THAT REGULATE THE ACTIVATION STATE OF Gi{alpha}
J. Biol. Chem., June 25, 2004; 279(26): 27567 - 27574.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Sato, T. W. Gettys, and S. M. Lanier
AGS3 and Signal Integration by G{alpha}s- and G{alpha}i-coupled Receptors: AGS3 BLOCKS THE SENSITIZATION OF ADENYLYL CYCLASE FOLLOWING PROLONGED STIMULATION OF A G{alpha}i-COUPLED RECEPTOR BY INFLUENCING PROCESSING OF G{alpha}i
J. Biol. Chem., April 2, 2004; 279(14): 13375 - 13382.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Adhikari and S. R. Sprang
Thermodynamic Characterization of the Binding of Activator of G Protein Signaling 3 (AGS3) and Peptides Derived from AGS3 with G{alpha}i1
J. Biol. Chem., December 19, 2003; 278(51): 51825 - 51832.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Ghosh, Y. K. Peterson, S. M. Lanier, and A. V. Smrcka
Receptor- and Nucleotide Exchange-independent Mechanisms for Promoting G Protein Subunit Dissociation
J. Biol. Chem., September 12, 2003; 278(37): 34747 - 34750.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. B. Blumer, M. L. Bernard, Y. K. Peterson, J.-i. Nezu, P. Chung, D. J. Dunican, J. A. Knoblich, and S. M. Lanier
Interaction of Activator of G-protein Signaling 3 (AGS3) with LKB1, a Serine/Threonine Kinase Involved in Cell Polarity and Cell Cycle Progression: PHOSPHORYLATION OF THE G-PROTEIN REGULATORY (GPR) MOTIF AS A REGULATORY MECHANISM FOR THE INTERACTION OF GPR MOTIFS WITH Gi{alpha}
J. Biol. Chem., June 20, 2003; 278(26): 23217 - 23220.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
R. J. Kimple, F. S. Willard, and D. P. Siderovski
The GoLoco Motif: Heralding a New Tango Between G Protein Signaling and Cell Division
Mol. Interv., April 1, 2002; 2(2): 88 - 100.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/9/6767    most recent
C100699200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, Y. K.
Right arrow Articles by Lanier, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, Y. K.
Right arrow Articles by Lanier, S. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.